SK Bioscience Co

SK Bioscience Co ROCE

The Return on Capital Employed (ROCE) of SK Bioscience Co (302440.KS) as of Oct 27, 2026 is -6.06 %. In the previous year, Return on Capital Employed (ROCE) was -6.84 % — a change of -11.44% (higher).

ROCE

-6.06 %

YoY

-11.44%

Last updated:

In 2025, SK Bioscience Co's return on capital employed (ROCE) was -6.06 %, a -11.44% increase from the -6.84 % ROCE in the previous year.

The SK Bioscience Co ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2018
1.56 KRW
Jan 1, 2019
2.78 KRW
Jan 1, 2020
14.30 KRW
Jan 1, 2021
29.61 KRW
Jan 1, 2022
6.60 KRW
Jan 1, 2023
-0.70 KRW
Jan 1, 2024
-6.84 KRW
Jan 1, 2025
-6.06 KRW
The SK Bioscience Co ROCE history
YEARROCEYoY
-6.06 %-11.44%
-6.84 %+872.86%
-0.70 %-110.65%
6.60 %-77.70%
29.61 %+107.16%
14.30 %+414.35%
2.78 %+78.36%
1.56 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

SK Bioscience Co Stock analysis

What does SK Bioscience Co do? SK Bioscience Co Ltd is a South Korean biotechnology company headquartered in Seongnam, Gyeonggi-Do. The company went public on March 18, 2021, with its stock listed on the Korean Stock Exchange under the ticker 302440.KS. It operates within the health care sector, specifically in the biotechnology industry. SK Bioscience employs 1,067 people and focuses on the development and distribution of bio and vaccine products. The company distributes its products both domestically and internationally. While specific product names are mentioned in unverified sources, the company is known to be involved in the production of vaccines and infusion solutions. It also engages in technology export business, though detailed information about its technology or export markets is not provided. The company's website is https://www.skbioscience.co.kr/, where further information about its operations and products may be available. SK Bioscience does not disclose specific details about its product lines beyond the general categories of vaccines and infusion solutions, and it does not provide information on acquisitions, founding year, or key personnel. The company's activities are centered around biotechnology and healthcare, with a focus on vaccine development and distribution. Its market presence spans both domestic and international markets, though specific regions or countries are not specified. The company's financial data, including revenue and market capitalization, is not included in the provided information. SK Bioscience is a publicly traded company with a focus on biotechnology and healthcare innovation. SK Bioscience Co is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling SK Bioscience Co's Return on Capital Employed (ROCE)

SK Bioscience Co's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing SK Bioscience Co's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

SK Bioscience Co's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in SK Bioscience Co’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about SK Bioscience Co stock

Return on Capital Employed (ROCE) of SK Bioscience Co is -6.06 % in 2025.

Return on Capital Employed (ROCE) of SK Bioscience Co changed from -6.84 % to -6.06 %, representing a -11.44% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) SK Bioscience Co since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s SK Bioscience Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — SK Bioscience Co

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — SK Bioscience Co